Court overturns practice on unlawful deprivation

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

Court overturns practice on unlawful deprivation

As in several other jurisdictions, in Germany a patent belongs to the inventor or his successor in title. If this right is infringed, the lawful owner has two options, namely filing a suit for the recovery of his property with an ordinary court, or filing an opposition with the German Patent Office (DPMA), within the opposition period of three months. The latter option offers the unique opportunity to file a new patent application claiming priority of the unlawful application.

In the past, the German Federal Court of Justice (Bundesgerichtshof, BGH), held the opinion that non-patentable subject matter cannot be the subject of an unlawful deprivation. This view was in contrast to the proceedings in a suit for recovery of property where the patentability is not a prerequisite, and is not even considered.

In a recent decision, the BGH abandoned the previously held opinion and ruled – by confirming a previous decision of the Federal Patent Court – that a decision on the unlawful deprivation only, without considering the patentability, can be justified (X ZB 43/08 – Schweißheizung, February 22 2011). The decision is based on the unique right to re-file the application given to the opponent only in opposition proceedings.

In the underlying case, company C filed an opposition against a patent co-owned by C and two inventors BA and SO. Before filing the opposition, the company acquired the right of the patent from two further inventors co-owning the patent. It turned out that BA was not a true inventor, and the rights of SO were legally transferred to C in accordance with employee invention law. Originally, the application was filed by SO as the only applicant, who later transferred the application to all four inventors by obtaining the necessary signatures by fraud. In this specific constellation, the unique right to re-file the application justifies the filing of an opposition against the own co-owned patent. This truly is an exceptional case.

braun.jpg

Nils Braun


Maiwald Patentanwalts GmbH

Elisenhof, Elisenstr 3

D-80335, Munich, Germany

Tel: +49 89 74 72 660

Fax: +49 89 77 64 24

info@maiwald.eu

www.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

Junior lawyers aren’t unwilling to work hard, as some seniors believe; rather, they are rejecting traditional career advancement models that have limited payoff
Rebekah Gay discusses overcoming self-doubt, supporting the next generation of women lawyers, and how changing client demands are reshaping IP practice
New filing data suggests Germany's grip on UPC litigation remains strong, while Bardehle Pagenberg, Arnold Ruess, Hogan Lovells and Carpmaels notch up notable cases
In 27 years, KASS has expanded to seven countries in southeast Asia and is now eyeing further growth opportunities. Its CEO shares her perspective
Mine Güner discusses bridging law and business, taking the initiative, and why Taylor Swift helped put copyright on the map
Cindy Goh discusses why she launched Cheang & Ariff's IP department, the improving litigation environment in Malaysia and what to consider when using AI
Increased focus on adding patent litigation depth to the firm’s Dallas office was behind the boutique’s most recent hires
IPH's Canadian acquisitions are paying off on paper, but a couple of strong years may not be enough to show that the group's strategy has truly won over the market
Examiner statistics could help patent prosecution practitioners tailor strategies, turning an area of high variability into a potential competitive advantage
The England and Wales High Court’s ruling in Accord v Novartis may not rewrite the law on plausibility, but it does signal a pragmatic approach that could provide greater certainty for life sciences innovators
Gift this article